Noxopharm Share Price and Company Fundamentals



Price
$0.235
Change
0.010 (4.444%)
52 week
0.17 - 0.63

Last traded: Today at 6:11 AM

Noxopharm Limited, a drug development company, engages in the research and development of drugs for the treatment of cancer and prevention of septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Noxopharm Limited has a partnership with Hudson Institute of Medical Research and a collaboration with The Australian National University to develop a better treatment for septic shock, as well as materials cooperative research and development agreement with the U.S. National Cancer Institute for treatment of brain cancer. The company was incorporated in 2015 and is based in Chatswood, Australia.

Key Metrics

PE ratio

-

PB ratio

1.96

Dividend yield

0.00%

Beta

1.57

Market cap

-

Enterprise value

-

Company profile

Primary activitiesNoxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine release syndrome (septic shock).
Industry / SectorBiotechnology / Healthcare
Websitehttps://www.noxopharm.com
Mailing addressTower A, The Zenith Level 20 821 Pacific Highway Chatswood NSW 2067 Australia
Phone / Fax /
Share registryAUTOMIC REGISTRY SERVICES

Dividends

More: Noxopharm Dividend history, yield and payout ratio

Dividend yield

0.00%

Dividend amount

$0.00

Payout ratio

0.00%

Noxopharm paid $0.00 dividend and the ex-dividend date was .The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.NOX dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.

NOX's forward dividend amount is $ and the forward dividend yield is . A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.

Company Executives

As of Aug 2022, following are the company executives and directors listed on Noxopharm.

NameTitleAgeTotal Pay
Mr. David James Franks B.Ec, BEc, CA, F Fin, JP.Company Sec.51
Dr. Gisela MautnerCEO, Exec. MD & Chief Medical Officer
Mr. Shawn Van BoheemenChief Financial Officer
Ms. Jeanette Bell Ph.D.Chief Operating Officer
Dr. John Wilkinson B.Sc., Ph.D.Chief Scientific Officer of Oncology
Dr. Olivier Laczka B.S., M.Sc., Ph.D.Chief Scientific Officer of Inflammation

Profitability and management effectiveness

Profit margin

-185.98%

Operating margin

-219.05%

Return on assets

-22.95%

Return on equity

-35.53%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Noxopharm is and its enterprise value is .

The NOX's stocks Beta value is 1.57 making it 57% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Noxopharm (NOX)

Noxopharm (ASX:NOX) Frequently Asked Questions

1. What is Noxopharm's Stock Symbol?

Noxopharm trades on ASX under the ticker symbol "NOX".

2. What is Noxopharm's stock price today?

One share of NOX stock can currently be purchased for approximately $0.235.

3. How can I contact Noxopharm?

Noxopharm's mailing address is Tower A, The Zenith Level 20 821 Pacific Highway Chatswood NSW 2067 Australia. The company can be reached via phone at .

4. What is Noxopharm's official website?

The official website of Noxopharm is https://www.noxopharm.com.

5. Which share registry manages Noxopharm's stock?

Noxopharm's stock is managed by AUTOMIC REGISTRY SERVICES.